UK pharmacy to offer Viagra without prescription, beginning Valentine’s Day

Share this article:
British pharmacy chain Boots plans to begin a trial program on Valentine’s Day to offer men Pfizer’s erectile dysfunction drug Viagra without a prescription, the Associated Press reports. The initial program will be available in three Boots stores in Manchester, 195 miles northwest of London. The Viagra pilot program is expected to last six months, after which the chain will consider whether to expand it to other pharmacies. Boots dominates the retail pharmacy sector in Britain, with about 1,500 stores. Would-be customers, between ages 30-65, will be required to see a pharmacist, provide a medical history and have their blood pressure, cholesterol and glucose levels tested. The consultation and a pack of four pills will cost 50 pounds ($98 USD). If customers want a refill, they will be required to see a doctor, according to a Boots spokeswoman. “It’s still very much a prescription drug,” Boots spokeswoman Clare Stafford told the AP. “This is just a different access point to it.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...